Machine learning redefines precision cancer therapy using smart radiopharmaceuticals
Posted:
JMIR Publications released a feature News and Perspectives story on technological advances in oncology. Authored by JMIR Correspondent Benedette Cuffari, "AI-Designed Radiopharmaceuticals: How Machine Learning Is Redefining Precision Cancer Therapy" reports on the integration of deep learning and generative AI in radiopharmaceutical medicine, its impact on accelerating drug design, and how personalized dosimetry can improve patient outcomes.
The VPodDuoss (the ‘V’ stands for virus)— can read and compare results from a variety of tests for pathogens or cancer-associated biomarkers.
It’s the brainchild of Lee, University of Illinois Urbana-Champaign Computer Engineering Professor Brian Cunningham, PhD, and Bioengineering Professor Xing Wang, PhD,…
Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear.
An international study led by Professor Henning Bundgaard, Professor of Cardiology at Rigshospitalet in Copenhagen, Denmark, and Dr Borja Ibáñez, Scientific Director of the Centro Nacional…